Derek J Lomas1, Amy E Krambeck2. 1. Department of Urology, Mayo Clinic, Rochester, MN. 2. Department of Urology, Mayo Clinic, Rochester, MN. Electronic address: gecoots2@gmail.com.
Abstract
OBJECTIVE: To evaluate long-term outcomes for men with benign prostatic obstruction (BPO) and concurrent detrusor underactivity (DUA) or acontractility following holmium laser enucleation of the prostate (HoLEP). METHODS: A retrospective chart review was performed on all patients with BPO and urodynamic evidence of DUA or acontractility secondary to a nonneurogenic etiology that underwent HoLEP at our institution over a 4-year period. Patients were included if they had at least 24 months of follow-up. RESULTS: We identified 9 patients with DUA and 8 patients with acontractility who met inclusion criteria with median ages of 76 and 75 years, respectively. Preoperatively, 7 (77.8%) men with DUA and 8 (100%) men with acontractility had catheter-dependent urinary retention for a median of 2 and 5 months, respectively. Postoperatively, 8 (88.9%) men with DUA and 5 (62.5%) men with acontractility were catheter free, with a median follow-up of 50.9 and 38.6 months, respectively. All the men requiring catheterization were voiding spontaneously, but used intermittent catheterization for elevated postvoid residuals. CONCLUSION: HoLEP appears to be an effective surgical option for patients with BPO and detrusor hypocontractility or acontractility, with durable results at follow-up greater than 24 months. However, patients with acontractile bladders should be counseled on possible need to for intermittent catheterization that may be needed for high postvoid residuals.
OBJECTIVE: To evaluate long-term outcomes for men with benign prostatic obstruction (BPO) and concurrent detrusor underactivity (DUA) or acontractility following holmium laser enucleation of the prostate (HoLEP). METHODS: A retrospective chart review was performed on all patients with BPO and urodynamic evidence of DUA or acontractility secondary to a nonneurogenic etiology that underwent HoLEP at our institution over a 4-year period. Patients were included if they had at least 24 months of follow-up. RESULTS: We identified 9 patients with DUA and 8 patients with acontractility who met inclusion criteria with median ages of 76 and 75 years, respectively. Preoperatively, 7 (77.8%) men with DUA and 8 (100%) men with acontractility had catheter-dependent urinary retention for a median of 2 and 5 months, respectively. Postoperatively, 8 (88.9%) men with DUA and 5 (62.5%) men with acontractility were catheter free, with a median follow-up of 50.9 and 38.6 months, respectively. All the men requiring catheterization were voiding spontaneously, but used intermittent catheterization for elevated postvoid residuals. CONCLUSION: HoLEP appears to be an effective surgical option for patients with BPO and detrusor hypocontractility or acontractility, with durable results at follow-up greater than 24 months. However, patients with acontractile bladders should be counseled on possible need to for intermittent catheterization that may be needed for high postvoid residuals.